{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:35Z","timestamp":1789340375320,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.xphs.2017.06.004","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:15:15Z","timestamp":1497485715000},"page":"3161-3166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Population Approach to Efavirenz Therapy"],"prefix":"10.1016","volume":"106","author":[{"given":"H\u00e9lder","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Aniceto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Clara","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","article-title":"Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection","volume":"73","author":"Csajka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2017.06.004_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200746020-00002","article-title":"Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring?","volume":"46","author":"Dahri","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"10.1016\/j.xphs.2017.06.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"issue":"40 Suppl 1","key":"10.1016\/j.xphs.2017.06.004_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0399-077X(10)70001-9","article-title":"[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor]","author":"Delaugerre","year":"2010","journal-title":"Med Mal Infect"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.004_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in\u00a0vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.xphs.2017.06.004_bib11","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in\u00a0vitro and in\u00a0vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.xphs.2017.06.004_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/pr.111.005553","article-title":"The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition","volume":"64","author":"Michaud","year":"2012","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/j.xphs.2017.06.004_bib14","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"Wyen","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":"Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers","volume":"320","author":"Faucette","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","article-title":"Viral hepatitis and HIV co-infection","volume":"85","author":"Soriano","year":"2010","journal-title":"Antivir Res"},{"issue":"3","key":"10.1016\/j.xphs.2017.06.004_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.47.1.130-137.2003","article-title":"Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS clinical trial group study 398 population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS clinical trial G","volume":"47","author":"Pfister","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2017.06.004_bib19","series-title":"Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools","author":"Lavielle","year":"2014"},{"issue":"2","key":"10.1016\/j.xphs.2017.06.004_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xphs.2017.06.004_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","article-title":"Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"issue":"11","key":"10.1016\/j.xphs.2017.06.004_bib22","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1128\/AAC.00194-11","article-title":"Population pharmacokinetic\/pharmacogenetic model for optimization of Efavirenz therapy in Caucasian HIV-infected patients","volume":"55","author":"S\u00e1nchez","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2017.06.004_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01059771","article-title":"Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis","volume":"21","author":"Wade","year":"1993","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"7","key":"10.1016\/j.xphs.2017.06.004_bib24","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1128\/AAC.01537-08","article-title":"Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients","volume":"53","author":"Cabrera","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2017.06.004_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In\u00a0vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.xphs.2017.06.004_bib26","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/AAC.01120-08","article-title":"Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine","volume":"53","author":"Zhu","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2017.06.004_bib27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/clpt.2010.172","article-title":"Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients","volume":"88","author":"Ngaimisi","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917304410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917304410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T18:03:27Z","timestamp":1659117807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917304410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0022354917304410"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.06.004","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Approach to Efavirenz Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}